SMS Pharmaceuticals Limited (NSE:SMSPHARMA)
India · Delayed Price · Currency is INR | Market Cap | 19.06B |
| Revenue (ttm) | 7.83B |
| Net Income (ttm) | 691.36M |
| Shares Out | 88.65M |
| EPS (ttm) | 8.16 |
| PE Ratio | 26.34 |
| Forward PE | n/a |
| Dividend | 0.40 (0.19%) |
| Ex-Dividend Date | Sep 23, 2024 |
| Volume | 65,283 |
| Average Volume | 77,677 |
| Open | 215.00 |
| Previous Close | 214.97 |
| Day's Range | 213.61 - 223.80 |
| 52-Week Range | 176.05 - 398.00 |
| Beta | 0.56 |
| RSI | 26.14 |
| Earnings Date | Aug 6, 2025 |
About CALT
SMS Pharmaceuticals Limited manufactures and sells active pharmaceutical ingredients (APIs) and its intermediates in India and internationally. The company offers anti-retroviral, anti-inflammatory, anti-viral, anti-diabetic, anti-fungal, anti-epileptic, anti-migraine, anti-coagulant, anti-psychotic, anti-aginal, and anti-ulcer products. It is also involved in contract research activities on peptides. The company exports its products to approximately 75 countries. SMS Pharmaceuticals Limited was incorporated in 1987 and is headquartered in Hyde... [Read more]
Financial Performance
In 2024, SMS Pharmaceuticals's revenue was 7.83 billion, an increase of 10.36% compared to the previous year's 7.09 billion. Earnings were 691.36 million, an increase of 38.75%.
Financial numbers in EUR Financial StatementsNews
SMS Pharmaceuticals share jump 6% after its Hyderabad facility clears USFDA inspection with zero observations
Shares of SMS Pharmaceuticals surged 6% in early trade after the company announced the successful completion of a USFDA inspection at its Central Laboratory Analytical Services in Gagillapur, Hyderaba...
SMS Pharmaceuticals clears second USFDA inspection at Hyderabad lab with zero observations
SMS Pharmaceuticals has recently informed exchanges that the company successfully completed its second inspection by the United States Food and Drug Administration (USFDA) at its Central Laboratory An...
SMS Pharmaceuticals’ Visakhapatnam facility receives WHO prequalification
SMS Pharmaceuticals Limited announced that its Unit VII manufacturing facility in Visakhapatnam, Andhra Pradesh, has received prestigious prequalification approval from the World Health Organisation (...
Stocks to Watch on Oct 3: Reliance Power, Ashoka Buildcon, CESC, SMS Pharma, PVR INOX, Zydus Lifesciences, Reliance Infra, and HealthCare Global in focus
Key stocks to watch include Ashoka Buildcon, CESC, SMS Pharmaceuticals, PVR INOX, HealthCare Global Enterprises, Zydus Lifesciences, Reliance Power, Reliance Infra, Vikas Lifecare, Eraaya Lifespaces, ...
SMS Pharmaceuticals receives EDQM certification to supply Ibuprofen in Europe
SMS Pharmaceuticals Limited (NSE: SMSPHARMA; BSE: 532815) has received the European Directorate for the Quality of Medicines & HealthCare (EDQM) certification to supply Ibuprofen from its Visakhapatna...